Deciphera Pharmaceuticals Inc $ 43.78 1.19 (2.79%)
Volume:
332,818
Avg Vol (1m):
463,781
Market Cap $:
2.52 Bil
Enterprise Value $:
2.00 Bil
PE Ratio:
0.00
PB Ratio:
4.61
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 17.68 | ||
| Equity-to-Asset | 0.85 | ||
| Debt-to-Equity | 0.06 | ||
| Debt-to-EBITDA | -0.12 | ||
| Piotroski F-Score | 2 | ||
| Altman Z-Score | 13.34 | ||
| Beneish M-Score | 0.64 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -644.36 | ||
| Net Margin % | -633.19 | ||
| ROE % | -45.15 | ||
| ROA % | -39.85 | ||
| ROC (Joel Greenblatt) % | -750.69 | ||
| 3-Year EBITDA Growth Rate | -16.7 | ||
| 3-Year EPS without NRI Growth Rate | -16.9 |
DCPH
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 4.61 | ||
| PS Ratio | 59 | ||
| EV-to-EBIT | -7.51 | ||
| EV-to-EBITDA | -7.58 | ||
| EV-to-Revenue | 47.57 | ||
| Current Ratio | 8.34 | ||
| Quick Ratio | 8.26 | ||
| Days Inventory | 6327.21 | ||
| Days Sales Outstanding | 120.51 | ||
| Days Payable | 19966.31 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.6 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.61 | ||
| Earnings Yield (Greenblatt) % | -13.32 |